Abstract
Programmed cell death is an important determinant of the response to chemotherapy. Among the factors controlling this process, a significant role is played by bcl-2, bax and p53. The in vitro chemosensitivity of the 177 breast carcinomas was assessed by the histoculture drug response assay (HDRA) using mitomycin C (MMC), 5-fluorouracil (5-Fu), adriamycin (ADM), cisplatin (CDDP), and cyclophosphamide (CPA). The susceptibility of Bcl-2-negative tumors to all the drugs killing was significantly higher than that of Bcl-2-positive tumors. No relationship between Bax or p53 immunoreactivity and sensitivity for any of anticancer drugs studied was demonstrated. Immunohistochemical results regarding Bcl-2 are promising in the evaluation of the sensitivity of cancer cells to a series of anticancer drugs and might be therapeutically useful as an indicator of response to adjuvant chemotherapy for breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Harris JR, Lippman ME, Verounesi U, Willett W: Breast cancer. N Engl J Med 327: 319–328, 1992
Xiaohui SL, Denmeade SR, Isaacs JT: The genetics of programmed (apoptotic) cell death. Cancer Surv 25: 173–194, 1995
Dive C, Hickman J: Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 64: 192–196, 1991
Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthemia. Biochem Pharmacol 40: 2353–2362, 1993
Sen S, D'Incalci M: Apoptosis. Biochemical events and relevance to enhancer chemotherapy. FEBS Lett 307: 122–127, 1992
Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957–967, 1993
Reed JC: Bcl-2: prevention of apoptosis and a mechanism of drug resistance. Hematol Oncol Clin North Am 9: 451–473, 1995
Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM: The t(14; 18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229: 1390–1393, 1985
Hockenbery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334–336, 1990
Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC: Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361: 365–369, 1993
Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1–6, 1994
Hollstein M, Sidransky D, Vogelstein B, Harris CC: P53 mutations in human cancers. Science 253: 49–53, 1991
Levine A, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351: 453–456, 1991
Sachs L, Lotem J: Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 82: 15–21, 1993
Davidoff AM, Kerns BJM, Iglehart JD, Marks JR: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88: 5006–5010, 1991
Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 65: 55–63, 1983
Furukawa T, Kubota T, Watanabc M, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K, Kitajima M: High in vitro- in vivo correlation of drug response using sponge-gel supported three-dimensional histoculture and the MTT endpoint. Int J Cancer 51: 489–498, 1992
Furukawa T, Kubota T, Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res 1: 305–311, 1995
Qifeng Yang, Takeo S, Xuefeng J, Hirotoshi U, Liang S, Yasushi N, Misa N, Shoji O, Takaomi S, Goro Y, Teiji U, Yozo K, Kennichi K: Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma. Pathol Int 49: 775–780, 1999
Beck WT: Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J Natl Cancer Inst 81: 1683–1685, 1989
Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313–4320, 1994
Lehnert M: Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 32: 912–920, 1996
McGill G, Fisher DE: Apoptosis in tumorigenesis and cancer therapy. Frontiers Biosci 2: 353–379, 1997
Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime-sempe C, Bodrug S, Kitada S, Hanada M: Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60: 23–32, 1996
Binder C, Marx D, Binder L, Schauer A, Hiddemann W: Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer. Ann Oncol 7: 129–133, 1996
Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Reed JC: Reduced expression of the proapoptotic gene BAX is associated with poor response rates to combined chemotherapy and shortened survival in women with metastatic breast carcinoma. Cancer Res 55: 4471–4478, 1995
Kapucuoglu N, Losi L, Eusebi V: Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive breast carcinomas. Virchows Arch 430: 17–22, 1997
Miyashita T, Kitada S, krajewski S, Horne WA, Delia D, Reed JC: Overexpression of the Bcl-2 protein increases the half-life of p21 (Bax). J Biol Chem 270: 26049–26052, 1995
Adams JM, Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322–1326, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, QF., Sakurai, T., Yoshimura, G. et al. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res Treat 61, 211–216 (2000). https://doi.org/10.1023/A:1006474307180
Issue Date:
DOI: https://doi.org/10.1023/A:1006474307180